SG Americas Securities LLC Sells 19,225 Shares of Boston Scientific Corporation $BSX

SG Americas Securities LLC decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 4.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 386,518 shares of the medical equipment provider’s stock after selling 19,225 shares during the period. SG Americas Securities LLC’s holdings in Boston Scientific were worth $36,854,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in BSX. Steph & Co. bought a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific during the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 2.3%

BSX opened at $69.70 on Thursday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The firm has a market capitalization of $103.59 billion, a PE ratio of 35.93, a P/E/G ratio of 1.05 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company’s 50-day moving average is $78.22 and its 200 day moving average is $91.25.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. UBS Group decreased their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a report on Monday, February 2nd. Needham & Company LLC reiterated a “buy” rating and set a $97.00 price target on shares of Boston Scientific in a report on Friday, March 20th. TD Cowen lowered their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Truist Financial dropped their price objective on Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $106.27.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support: TD Cowen highlighted strong early adoption of BSX’s Agent DCB and kept a Buy rating with a $100 price target, underpinning bullish investor sentiment on multi-year growth potential. Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
• Positive Sentiment: Potential rating upgrade / turnaround view: A Seeking Alpha piece argues BSX is “under pressure but could see a shift in fortunes,” suggesting a rating upgrade could help sentiment if upcoming operational data improves. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Positive Sentiment: Bullish “buy the dip” narratives: MarketBeat and other bullish write-ups view the recent pullback as an opportunity tied to pending trial results and long-term device adoption, supporting short-term buying interest. Why Boston Scientific’s Big Dip Could Be a Bigger Opportunity
• Neutral Sentiment: Industry note (unrelated company): Stratus Medical was named to Fortune’s Most Innovative Companies list — a positive for the RFA/chronic pain segment but not directly tied to BSX results. Investors may view it as a sector-level signal rather than company-specific news. Stratus Medical Recognized on Fortune’s America’s Most Innovative Companies List for 2026
• Negative Sentiment: Surge of securities-law firm notices and class-action filings allege misstatements around U.S. electrophysiology volumes; multiple firms (Bronstein, Faruqi, Levi & Korsinsky, Pomerantz, Rosen, Robbins, Bernstein Liebhard, etc.) are soliciting lead-plaintiff candidates and reminders about the May 4, 2026 deadline—heightening litigation risk and headline volatility for BSX. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Recent stock weakness and volatility: News outlets and Zacks noted BSX shares have recently traded down more sharply than the broader market, reflecting investor concern over guidance, electrophysiology volumes, and litigation headlines. Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.